Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Low Dose
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(128)
•••
Comment by MrMugsyon Sep 05, 2021 1:41pm
139 Views
Post# 33815655

RE:Low Dose

RE:Low Dose
TheMadMonk wrote: Do we have an estimated time frame for when we can expect the company to have a lowest effective dose for OTENA?


Hey MadMonk ... we are waiting to see if we can go lower than 100 mg ... that's what we need first.  Management said we'd know in October.  I sure hope they can better that.

1.  If we can't go lower then we should have a pretty good idea where the lowest is ... 100, 150 or 200 mg.  Make go-forward plans from there.

2.  If we can go lower, I would assume a second AME is in order and as we discussed here before ... might as well go the full range ... 75, 50, 25, 10, 5mg (or something similar) to ensure we find the lowest possible dose.

So ... if #2 is the right direction,  they'd need one month to apply (October) and receive the OK for AME and then we'd have to run it in Nov-Dec.  Somewhere before the end of Q1 2022 ????  

Just guessing.

Hope that helps.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities